Viatris: A bold history and bright future

Viatris was formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer. By integrating the strengths of these two companies, including our global workforce, we aim to deliver increased access to affordable, quality medicines for patients worldwide, regardless of geography or circumstance. Breaking from the traditional conventions that have ruled the pharmaceutical industry for nearly a century, the company is both large-scale and agile, persistent and reliable.

Our journey

Viatris seeks to empower Australians to live healthier at every stage of life by providing access to high quality, trusted medicines.

We believe better access to medicines leads to better health. Our proven local and global manufacturing and proven commercial capabilities help to bring quality medicines to patients when and where they need them.

We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to improve patient outcomes. In Australia, our origins can be traced to Alphapharm which pioneered generic manufacturing in Australia from the early 1980s.

We have a broad portfolio of quality medicines, including brands, generics, biosimilars and OTC products across more than 10 major therapeutic areas covering a wide variety of noncommunicable and infectious diseases.

The birth of Viatris

Travel back in time to see the separate stories of Mylan and Upjohn unfold, and learn how they came together to form Viatris.
Learn more